All In Biotech

Drug Trial Radar · NCT05281263

Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults

A Phase 1 Trial of the Safety, Tolerability, and Immunogenicity of BLB-201 Vaccine in Healthy Young Adults and Older Adults

Last checked: Nov 19, 2026Latest source record: Dec 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jul 20, 2022

Primary completion

Dec 5, 2022

Study completion May 3, 2023

Sponsor

Lead sponsor
Blue Lake Biotechnology Inc.Industry
Sponsor type
Industry
First posted
Mar 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1 trial is an open-label trial to evaluate the safety, tolerability and immunogenicity of a single dose (10\^7.5 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered as a single dose in 15 healthy young adults ages 18-59 years, and 15 older adults ages 60-75 years.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • CPI-RSV-F Vaccine (BLB-201)Biological

    see arm/group description

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Solicited Adverse EventsTime frame: Day 1-8
  2. Unsolicited Adverse EventsTime frame: Day 1-29

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Coastal Carolina Research Center

    North Charleston, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.